Literature DB >> 15246624

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.

Dennis M Klinman1, Hang Xie, Stephen F Little, Debra Currie, Bruce E Ivins.   

Abstract

Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune adjuvants, improving the immune response elicited by co-administered vaccines. Combining CpG ODN with anthrax vaccine adsorbed (AVA, the licensed human vaccine) increased the speed, magnitude and avidity of the resultant anti-anthrax response. The protective activity of these Abs was established by passive transfer to anthrax-challenged mice. The ability of CpG ODN to accelerate and magnify the immune response to AVA suggests this strategy may contribute to the development of prophylactic and therapeutic vaccines against biothreat pathogens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246624     DOI: 10.1016/j.vaccine.2003.12.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

Review 1.  Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy.

Authors:  Deborah M Brown
Journal:  Cell Immunol       Date:  2010-02-24       Impact factor: 4.868

Review 2.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

3.  TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants.

Authors:  Sarah C Higgins; Kingston H G Mills
Journal:  Curr Infect Dis Rep       Date:  2010-01       Impact factor: 3.725

4.  CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.

Authors:  Hang Xie; Ihsan Gursel; Bruce E Ivins; Manmohan Singh; Derek T O'Hagan; Jeffrey B Ulmer; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.

Authors:  Eric K Dumas; Melissa L Nguyen; Philip M Cox; Heidi Rodgers; Joanne L Peterson; Judith A James; A Darise Farris
Journal:  Vaccine       Date:  2013-02-13       Impact factor: 3.641

6.  Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.

Authors:  Dennis M Klinman; Sven Klaschik; Koji Tomaru; Hidekazu Shirota; Debra Tross; Hidekazu Ikeuchi
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

7.  Imprinting of Repeated Influenza A/H3 Exposures on Antibody Quantity and Antibody Quality: Implications for Seasonal Vaccine Strain Selection and Vaccine Performance.

Authors:  Martina Kosikova; Lei Li; Peter Radvak; Zhiping Ye; Xiu-Feng Wan; Hang Xie
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

8.  Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax.

Authors:  Dennis M Klinman; Debra Currie; Gloria Lee; Vanessa Grippe; Tod Merkel
Journal:  Microbes Infect       Date:  2007-08-10       Impact factor: 2.700

9.  In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model.

Authors:  Christina C N Wu; Mojgan Sabet; Tomoko Hayashi; Rommel Tawatao; Joshua Fierer; Dennis A Carson; Donald G Guiney; Maripat Corr
Journal:  Cell Immunol       Date:  2008-05-20       Impact factor: 4.868

10.  Effect of CpG oligonucleotides on vaccine-induced B cell memory.

Authors:  Debra Tross; Dennis M Klinman
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.